HealthQuill AstraZeneca Plc.
AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from the European Union.
Drugs Health Pharma

AstraZeneca’s lung cancer drug combination gets EU approval 

HQ Team April 4, 2025: AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from.

Read More
Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European Union, the companies announced.
Drugs Medical Pharma

EU green lights AstraZeneca, Daiichi’s treatment for breast cancer

HQ Team April 4, 2025: Daiichi Sankyo and AstraZeneca’s treatment for breast cancer, Enhertu, has been approved as a monotherapy in the European.

Read More
AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the Anglo-Swedish company.
Drugs Health Pharma

AstraZeneca says trial breast cancer drug improves survival rates

AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Uncategorized

EU panel gives a positive opinion for AstraZeneca’s cancer drug

AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Drugs Medical Pharma

AstraZeneca’s drug gets nod to treat limited-stage cell lung cancer patients

The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.

Read More
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Health Pharma

AstraZeneca to invest $3.5 billion in the US to expand global footprint

Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of.

Read More
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s drug to treat rare blood vessel disease gets EU nod

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

Read More